Loading...
01/11 07:35
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call revealed several negative indicators: decreased EPS guidance, flat or declining revenues in key areas, and decreased profit margins. The Q&A highlighted competitive pressures and uncertainties in the PYLARIFY market, alongside management's lack of clarity on certain issues. Despite strategic partnerships and divestitures aimed at future growth, the current financial performance and guidance adjustments suggest a negative short-term outlook for the stock.
Consolidated Net Revenue $372.8 million, an increase of 0.8% year-over-year.
Radiopharmaceutical Oncology Revenue (PYLARIFY) $257.7 million, flat year-over-year.
Precision Diagnostics Revenue $104.4 million, flat year-over-year.
DEFINITY Sales $79.2 million, an increase of 3.5% year-over-year.
TechneLite Revenue $19.7 million, a decrease of 9.2% year-over-year due to a brief supply issue.
Strategic Partnerships and Other Revenue $10.7 million, an increase of 65.1% year-over-year due to contributions from MK-6240 and a milestone sale.
Gross Profit Margin 67%, a decrease of 180 basis points year-over-year due to strategic partnership contracting initiatives and unfavorable dose volume mix.
Operating Expenses 28.3% of net revenue, an increase of 147 basis points year-over-year due to investments in growth and efficiency initiatives.
Operating Profit $144.3 million, a decrease of 7.1% year-over-year.
GAAP Net Income $72.9 million, a decrease of 7.5% year-over-year.
Adjusted Net Income $109.5 million, a decrease of 7.5% year-over-year.
GAAP Fully Diluted Earnings Per Share $1.02, a decrease of 9.5% year-over-year.
Adjusted Earnings Per Share $1.53, a decrease of 9.5% year-over-year.
Operating Cash Flow $107.6 million, a decrease of $19.7 million year-over-year.
Capital Expenditures $8.7 million, $400,000 lower year-over-year.
Free Cash Flow $98.8 million, a decrease of $20.1 million year-over-year.
Cash and Cash Equivalents $938.5 million at the end of Q1.
Effective Tax Rate 26.5%.
PYLARIFY Sales: PYLARIFY sales for Q1 2025 were $258 million, with year-over-year volume growth offset by low-single-digit decline in net price.
DEFINITY Sales: DEFINITY achieved approximately $79 million in sales in Q1 2025, maintaining its position as the number one utilized ultrasound enhancing agent.
NEURACEQ: LMI acquisition includes NEURACEQ, a globally approved F-18 PET imaging agent for Alzheimer’s disease.
OCTEVY: Evergreen acquisition includes OCTEVY, a registrational stage PET imaging agent targeting neuroendocrine tumors.
MK-6240: MK-6240, a next-generation tau imaging agent, met primary endpoints in pivotal studies and plans for FDA submission in Q3 2025.
Alzheimer's Radiodiagnostic Market: The U.S. Alzheimer's radiodiagnostics total addressable market could grow to over $1.5 billion by the end of the decade and $2.5 billion by the mid-2030s.
PSMA PET Addressable Market: By 2030, the PSMA PET addressable market is anticipated to exceed $3.5 billion.
Acquisitions: Lantheus announced two acquisitions in Q1 2025: Evergreen Theragnostics and Life Molecular Imaging, aimed at enhancing radiopharmaceutical leadership.
SPECT Business Divestment: Lantheus plans to divest its SPECT business to SHINE Technologies, focusing on PET radiodiagnostics.
Focus Shift: The divestment of the SPECT business allows Lantheus to concentrate on PET radiodiagnostics, microbubbles, and radiotherapeutic agents.
Integration Focus: The company is focused on integrating the Evergreen and LMI businesses and finalizing the divestment of the SPECT business.
Competitive Pressures: The company anticipates competitive disruption among smaller, non-contracted sites due to the expiry of PYLARIFY's pass-through status and the implementation of mean unit cost payment for Medicare.
Regulatory Issues: The company is actively monitoring recent tariff activity and assessing potential impacts on their business, advocating for continued exceptions granted to pharmaceuticals and radioisotopes.
Supply Chain Challenges: A brief supply issue with TechneLite in March impacted revenue, although it has since been resolved.
Economic Factors: The company expects low-single-digit growth for PYLARIFY revenue for the full year, down from previous expectations, indicating potential economic pressures affecting sales.
Integration Risks: The integration of the recently acquired Evergreen and LMI businesses poses risks related to operational efficiency and the realization of projected synergies.
Divestiture Risks: The divestiture of the SPECT business may lead to transitional challenges, although it is expected to unlock future revenue growth and margin expansion.
Divestiture of SPECT Business: Lantheus announced plans to divest its SPECT business to SHINE Technologies, focusing on PET radiodiagnostics and radiotherapeutic agents.
Acquisitions of Evergreen and LMI: The acquisitions are aimed at enhancing radiopharmaceutical leadership, diversifying revenue, and adding capabilities for novel programs.
Revenue Growth Drivers: The acquisitions are expected to add immediate revenue growth drivers and enhance the company's long-term growth potential.
Market Expansion Opportunities: The company anticipates significant growth in the Alzheimer’s radiodiagnostic market, projecting a total addressable market of over $1.5 billion by the end of the decade.
R&D Investments: R&D is expected to be approximately 7.5% of revenue, reflecting increased investments in late- and early-stage development programs.
2025 Revenue Guidance: Total revenue is now expected to be between $1.55 billion and $1.585 billion, with PYLARIFY performance adjusted to flat-to-low single-digit percent growth.
Adjusted EPS Guidance: Adjusted EPS is projected to be in the range of $6.60 to $6.70, down from the previous guidance of $7 to $7.20.
Impact of Acquisitions on EPS: The acquisitions of Evergreen and LMI are expected to dilute adjusted EPS by approximately $0.25.
SPECT Business Impact: The divestiture of the SPECT business is not expected to impact 2025 revenue or earnings.
Shareholder Return Plan: The company is focused on returning value to shareholders through disciplined capital allocation strategies and investments in capabilities. They have a strong cash position of $938.5 million and access to a $750 million undrawn bank revolver.
Free Cash Flow: Free cash flow for Q1 2025 was $98.8 million.
Adjusted EPS Guidance: The adjusted EPS is now expected to be in the range of $6.60 to $6.70 for the full year 2025, down from the prior guidance of $7 to $7.20.
Divestiture Impact: The divestiture of the SPECT business is expected to unlock consolidated revenue growth and gross margin expansion in the future, although it will not impact 2025 revenue or earnings.
The earnings call reveals several negative indicators: reduced revenue guidance, declining gross profit margins, and increased operating expenses. The Q&A section shows management's reluctance to provide specific guidance for 2026, adding uncertainty. Despite some positives like new product launches and a stock repurchase program, the overall sentiment is negative due to financial declines and management changes. These factors, combined with competitive pressures and lack of clear future direction, suggest a likely negative stock price movement.
The earnings call presents a mixed outlook. While there are positive elements such as expected revenue growth from acquisitions and market expansion opportunities, there are concerns regarding declining EPS guidance and pricing pressures on PYLARIFY. The Q&A highlighted uncertainties in contract dynamics and market competition. Despite potential growth in Alzheimer's diagnostics, the flat PYLARIFY growth and the impact of acquisitions on EPS dilute the overall sentiment. The absence of clear guidance on certain aspects further adds to the neutral stance.
The earnings call presents mixed signals. While strategic partnerships and other revenue increased significantly, core areas like PYLARIFY and Precision Diagnostics remained flat. The company faces competitive challenges and has reduced its EPS guidance, indicating potential short-term struggles. However, optimistic long-term growth potential in the Alzheimer's diagnostic market and strategic transactions could offset these concerns. The market reaction is likely to be neutral, reflecting the balance between short-term challenges and long-term optimism.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
